Compare · BCDA vs MRNA
BCDA vs MRNA
Side-by-side comparison of BioCardia Inc. (BCDA) and Moderna Inc. (MRNA): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BCDA and MRNA operate in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care), so they compete in similar markets.
- MRNA is the larger of the two at $56.02B, about 3334.0x BCDA ($16.8M).
- MRNA has been more active in the news (20 items in the past 4 weeks vs 5 for BCDA).
- MRNA has more recent analyst coverage (25 ratings vs 1 for BCDA).
- Company
- BioCardia Inc.
- Moderna Inc.
- Price
- -
- -
- Market cap
- $16.8M
- $56.02B
- 1M return
- +12.05%
- -
- 1Y return
- -47.87%
- -
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- News (4w)
- 5
- 20
- Recent ratings
- 1
- 25
BioCardia Inc.
BioCardia, Inc., a clinical-stage regenerative medicine company, develops therapeutics for cardiovascular diseases. Its lead therapeutic candidate is the CardiAMP Cell Therapy System for the treatment of heart failure and chronic myocardial ischemia; and ALLOGENEIC cell therapy for cardiac and pulmonary disease. The company is also developing ALLOGENEIC Cell Therapy System, an investigational culture expanded bone marrow derived mesenchymal cell therapy, which is in Phase I/II trial for the treatment of ischemic systolic heart failure. In addition, it offers the Helix biotherapeutic delivery system, a percutaneous catheter delivery system for cardiovascular regenerative medicine; and Morph deflectable guides and sheaths. The company is based in San Carlos, California.
Moderna Inc.
Moderna, Inc., a biotechnology company, develops therapeutics and vaccines based on messenger RNA for the treatment of infectious diseases, immuno-oncology, rare diseases, cardiovascular diseases, and auto-immune diseases. As of March 9, 2021, the company had 13 programs in clinical trials and a total of 24 development programs in six modalities comprising prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted and cell surface therapeutics, and systemic intracellular therapeutics. The company has strategic alliances with AstraZeneca PLC, Merck & Co., Inc., Vertex Pharmaceuticals Incorporated, Vertex Pharmaceuticals (Europe) Limited, the Biomedical Advanced Research and Development Authority, the Defense Advanced Research Projects Agency, the National Institute of Allergy and Infectious Diseases, the National Institutes of Health, the Coalition for Epidemic Preparedness Innovations, and Bill & Melinda Gates Foundation. Moderna, Inc. also has collaborations with Lonza Ltd. for the manufacture of COVID-19 vaccine; and Catalent Inc., Laboratorios Farmacéuticos Rovi, S.A., Recipharm, and Lonza Group for fill-finish manufacturing of its COVID-19 vaccine candidate, as well as Aldevron, LLC for supporting COVID-19 vaccine and additional programs in company's clinical development pipeline. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.
Latest BCDA
- President and CEO Altman Peter bought $872 worth of shares (800 units at $1.09), increasing direct ownership by 0.21% to 381,985 units (SEC Form 4)
- BioCardia Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- BioCardia Announces FDA Confirms Helix Transendocardial Delivery Catheter Meeting Minutes Supporting Follow-On De Novo Pre-Submission for Approval
- BioCardia Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
- President and CEO Altman Peter bought $5,022 worth of shares (5,400 units at $0.93), increasing direct ownership by 1% to 381,115 units (SEC Form 4)
- President and CEO Altman Peter bought $1,748 worth of shares (1,900 units at $0.92), increasing direct ownership by 0.51% to 375,785 units (SEC Form 4)
- BioCardia Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- SEC Form 10-Q filed by BioCardia Inc.
- BioCardia Reports Second Quarter 2026 Business Highlights and Financial Results
- BioCardia to Host Q2 2026 Financial Results and Corporate Update Conference Call on August 12, 2026
Latest MRNA
- Chief Financial Officer Mock James M converted options into 11,797 shares and covered exercise/tax liability with 5,704 shares, increasing direct ownership by 9% to 74,375 units (SEC Form 4) (for tax liability)
- Chief Legal Officer Klinger Shannon Thyme covered exercise/tax liability with 5,704 shares and converted options into 11,797 shares, increasing direct ownership by 8% to 81,340 units (SEC Form 4) (withholding obligation)
- Chief Legal Officer Klinger Shannon Thyme sold $485,766 worth of shares (3,471 units at $139.95) as part of a pre-agreed trading plan, covered exercise/tax liability with 1,048 shares and exercised 5,637 shares at a strike of $19.06, increasing direct ownership by 2% to 75,247 units (SEC Form 4) to cover withholding tax
- Chief Financial Officer Mock James M covered exercise/tax liability with 1,197 shares and converted options into 2,475 shares, increasing direct ownership by 2% to 68,282 units (SEC Form 4) (for withholding tax)
- President Hoge Stephen converted options into 9,283 shares and covered exercise/tax liability with 4,489 shares, increasing direct ownership by 0.32% to 1,489,699 units (SEC Form 4) (tax liability)
- Moderna downgraded by Rothschild & Co Redburn with a new price target
- Moderna Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement
- Moderna to Present at Upcoming Conferences in September 2026
- President Hoge Stephen converted options into 2,048 shares and covered exercise/tax liability with 991 shares, increasing direct ownership by 0.07% to 1,484,905 units (SEC Form 4) to satisfy tax liability
- Chief Legal Officer Klinger Shannon Thyme converted options into 1,103 shares and covered exercise/tax liability with 535 shares, increasing direct ownership by 0.77% to 74,129 units (SEC Form 4) to cover withholding tax